BSI statement on extension of self-isolation period following COVID-19 symptoms from seven to ten days
BSI response to results of phase 1/2 trial of a vaccine against SARS-CoV-2 by Oxford University
BSI response to new research on COVID-19 immune response.
BSI response to the first in human clinical trials of a new vaccine against COVID-19 from Imperial College London
Today, world leaders have come together at Gavi’s donor pledging conference, the Global Vaccine Summit, which aimed to mobilise at least $7.4 billion towards Gavi’s next strategic cycle (2021-25). Gavi has received $8.8 billion in contributions which surpasses that goal and will protect the next generation through vaccination. In response, the British Society for Immunology has released the following statement.
BSI response to approval of an antibody test against COVID-19 by Public Health England
Our statement on 40 years since smallpox was eradicated.
British Society for Immunology response to recently announced membership of the Scientific Advisory Group for Emergencies (SAGE)
A new report from the British Society for Immunology and Academy of Medical Science summarising what we do and don't know about immunology and COVID-19 and identifying research priorities.
British Society for Immunology response to new funding announced by UK Government for Gavi, the Vaccine Alliance
British Society for Immunology report highlighting the UK's contribution to vaccine research
Our response to a commentary from the Journal of the Royal Society of Medicine on the evidence around current UK Government guidelines for social distancing/isolation for COVID-19 for people aged 60-69.
BSI response to Government announcement of the creation of a Vaccine Taskforce to drive forward work on a vaccine against COVID-19.
British Society for Immunology response to University of Oxford's announcement that their COVID-19 vaccine programme has opened for clinical trial recruitment.
British Society for Immunology response to six new research projects that the UK government is funding to develop active interventions against the novel coronavirus